Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Safety and efficacy of vedoliz...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group

Safety and efficacy of vedolizumab in pediatric inflammatory bowel disease with emphasis on the very-early-onset group

Bibliographic Details
Main Authors: Sylwia Fabiszewska, Edyta Derda, Edyta Szymańska, Marcin Osiecki, Jarosław Kierkuś
Format: Article
Language:English
Published: Termedia Publishing House 2023-06-01
Series:Pediatria Polska
Subjects:
crohn disease
ulcerative colitis
vedolizumab
pediatric inflammatory bowel disease
very-early-onset inflammatory bowel disease.
Online Access:https://www.termedia.pl/Safety-and-efficacy-of-vedolizumab-in-pediatric-inflammatory-bowel-disease-with-emphasis-on-the-very-early-onset-group,127,50882,1,1.html
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.termedia.pl/Safety-and-efficacy-of-vedolizumab-in-pediatric-inflammatory-bowel-disease-with-emphasis-on-the-very-early-onset-group,127,50882,1,1.html

Similar Items

  • Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
    by: Vitaliy Y. Poylin, et al.
    Published: (2022-01-01)
  • Remission Is Maintained after Switch from Dose-Optimised Intravenous Treatment to Subcutaneous Treatment with Vedolizumab in Inflammatory Bowel Disease
    by: Špela Pintar, et al.
    Published: (2024-02-01)
  • Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
    by: Timo Rath, et al.
    Published: (2018-07-01)
  • Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
    by: Lieven Pouillon, et al.
    Published: (2019-05-01)
  • High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
    by: Manuel Sutter, et al.
    Published: (2021-08-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs